EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Amphiregulin blockade decreases the levodopa‐induced dyskinesia in a 6‐hydroxydopamine Parkinson's disease mouse model

Piniel Alphayo Kambey iD, Wen Ya Liu, Jiao Wu, Chuanxi Tang, Wokuheleza Buberwa, Adonira Saro, Alphonce M K Nyalali, Dianshuai Gao iD

CNS Neuroscience & Therapeutics · 2023

DOI: 10.1111/cns.14229 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, 2023. Verfasst von Piniel Alphayo Kambey und 7 weiteren Autor:innen. Beteiligte Einrichtung: Xuzhou Key Laboratory of Neurobiology, Department of Neurobiology and Anatomy, Xuzhou Medical University, Xuzhou, China. Hauptthemen laut MEDLINE: Parkinson Disease, Dyskinesia, Drug-Induced. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Levodopa (L‐DOPA) is considered the most reliable drug for treating Parkinson's disease (PD) clinical symptoms. Regrettably, long‐term L‐DOPA therapy results in the emergence of drug‐induced abnormal involuntary movements (AIMs) in most PD patients. The mechanisms underlying motor fluctuations and dyskinesia induced by L‐DOPA (LID) are still perplexing.

Methods

Here, we first performed the analysis on the microarray data set (GSE55096) from the gene expression omnibus (GEO) repository and identified the differentially expressed genes (DEGs) using linear models for microarray analysis (Limma) R packages from the Bioconductor project. 12 genes ( Nr4a2, Areg, Tinf2, Ptgs2, Pdlim1, Tes, Irf6, Tgfb1, Serpinb2, Lipg, Creb3l1, Lypd1 ) were found to be upregulated. Six genes were validated on quantitative polymerase chain reaction and subsequently, Amphiregulin ( Areg ) was selected (based on log2 fold change) for further experiments to unravel its involvement in LID. Areg LV_shRNA was used to knock down Areg to explore its therapeutic role in the LID model.

Results

Western blotting and immunofluorescence results show that AREG is significantly expressed in the LID group relative to the control. Dyskinetic movements in LID mice were alleviated by Areg knockdown, and the protein expression of delta FOSB, the commonly attributable protein in LID, was decreased. Moreover, Areg knockdown reduced the protein expression of P‐ERK. In order to ascertain whether the inhibition of the ERK pathway (a common pathway known to mediate levodopa‐induced dyskinesia) could also impede Areg , the animals were injected with an ERK inhibitor (PD98059). Afterward, the AIMs, AREG, and ERK protein expression were measured relative to the control group. A group treated with ERK inhibitor had a significant decrease of AREG and phosphorylated ERK protein expression relative to the control group.

Conclusion

Taken together, our results indicate unequivocal involvement of Areg in levodopa‐induced dyskinesia, thus a target for therapy development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseDyskinesia, Drug-InducedMiceAnimalsLevodopaOxidopamineAntiparkinson AgentsAmphiregulinDisease Models, Animal

Stichwörter der Autor:innen

AmphiregulinParkinson's diseasedyskinesialevodopa

Substanzen

LevodopaOxidopamineAntiparkinson AgentsAmphiregulin

Autor:innen und Institutionen

  • Xuzhou Key Laboratory of Neurobiology, Department of Neurobiology and Anatomy, Xuzhou Medical University, Xuzhou, China.
  • Organization of African Academic Doctors (OAAD), Nairobi, Kenya.
  • Department of Pediatrics, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
  • Department of Anatomy and Neurobiology, School of Basic Medical Science, Central South University, Changsha, China.
  • Department of Neurosurgery, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.

ORCID-Profile: Piniel Alphayo Kambey, Dianshuai Gao

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Kambey, P. A., Liu, W. Y., Wu, J., Tang, C., Buberwa, W., Saro, A., Nyalali, A. M. K., & Gao, D. (2023). Amphiregulin blockade decreases the levodopa‐induced dyskinesia in a 6‐hydroxydopamine Parkinson's disease mouse model. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/cns.14229

Vancouver

Kambey PA, Liu WY, Wu J, Tang C, Buberwa W, Saro A, et al. Amphiregulin blockade decreases the levodopa‐induced dyskinesia in a 6‐hydroxydopamine Parkinson's disease mouse model. CNS Neuroscience & Therapeutics. 2023. doi:10.1111/cns.14229

BibTeX
@article{Kambey2023,
  author = {Kambey, Piniel Alphayo and Liu, Wen Ya and Wu, Jiao and Tang, Chuanxi and Buberwa, Wokuheleza and Saro, Adonira and Nyalali, Alphonce M K and Gao, Dianshuai},
  title = {Amphiregulin blockade decreases the levodopa‐induced dyskinesia in a 6‐hydroxydopamine Parkinson's disease mouse model},
  journal = {CNS Neuroscience & Therapeutics},
  year = {2023},
  doi = {10.1111/cns.14229}
}
Kostenlos starten →